Peptide Library

FDA-approved

Skin & aging

Icatibant

Evidence

FDA approved

Class

Bradykinin B2 receptor antagonist

/

Icatibant

KEY TAKEAWAY

Icatibant is a synthetic ten-amino-acid peptide that resembles bradykinin. It is sold as Firazyr and as generics. The FDA approved icatibant (Firazyr) in 2011 for acute attacks of hereditary angioedema in adults, and later for younger patients.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Bradykinin B2 receptor antagonist

Approved for

Acute attacks of hereditary angioedema

Key fact

The FDA approved icatibant (Firazyr) in 2011 for acute attacks of hereditary angioedema in adults, and later for younger patients.

Route

Subcutaneous injection that patients can learn to give themselves

Evidence strength

FDA approved

What it is

What it is

Icatibant is a synthetic ten-amino-acid peptide that resembles bradykinin. It is sold as Firazyr and as generics.

How it works

How it works

It blocks the bradykinin B2 receptor, which prevents the swelling and pain of hereditary angioedema attacks.

Regulatory status

Regulatory status

The FDA approved icatibant (Firazyr) in 2011 for acute attacks of hereditary angioedema in adults, and later for younger patients.

What it is used for

What it is used for

Acute attacks of hereditary angioedema.

Side effects and risks

Side effects and risks

Redness, swelling and pain at the injection site are very common. Dizziness and fever can occur.

Citations

Citations

U.S. FDA prescribing information for Icatibant. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo